Philippe Solal-Celigny

Summary

Country: France

Publications

  1. ncbi Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden
    P Solal-Celigny
    Centre Jean Bernard, Le Mans, France
    Anticancer Drugs 12:S11-4. 2001
  2. ncbi Follicular lymphoma international prognostic index
    Philippe Solal-Celigny
    Centre Jean Bernard, 9 rue Beauverger, 72000 Le Mans, France
    Blood 104:1258-65. 2004
  3. ncbi Prognosis of follicular lymphomas
    Philippe Solal-Celigny
    Department of Hematology and Medical Oncology, Centre Jean Bernard, Le Mans, France
    Clin Lymphoma 6:21-5. 2005
  4. ncbi Safety of rituximab maintenance therapy in follicular lymphomas
    Philippe Solal-Celigny
    Department of Hematology and Medical Oncology, Jean Bernard Cancer Centre, Le Mans, France
    Leuk Res 30:S16-21. 2006
  5. ncbi Increasing treatment options in indolent non-Hodgkin's lymphoma
    Philippe Solal-Celigny
    Jean Bernard Cancer Centre, Le Mans, France
    Semin Oncol 29:2-6. 2002
  6. ncbi Follicular Lymphoma International Prognostic Index
    Philippe Solal-Celigny
    Centre Jean Bernard, 9 rue Beauverger, 72000 Le Mans, France
    Curr Treat Options Oncol 7:270-5. 2006
  7. ncbi What is the optimal prognostic tool for the assessment of patients with newly diagnosed follicular lymphoma?
    Philippe Solal-Celigny
    Centre Jean Bernard, Le Mans, France
    Leuk Lymphoma 48:452-3. 2007
  8. ncbi [Monoclonal anti-CD20 antibody therapy]
    Laurence Juhel
    Centre Jean Bernard, Le Mans
    Rev Prat 54:711-2. 2004
  9. ncbi Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks
    Gérard Ganem
    Department of Radiation Oncology, Centre Jean Bernard, Le Mans, France
    Int J Radiat Oncol Biol Phys 78:975-82. 2010

Detail Information

Publications9

  1. ncbi Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden
    P Solal-Celigny
    Centre Jean Bernard, Le Mans, France
    Anticancer Drugs 12:S11-4. 2001
    ..Rituximab monotherapy is therefore an effective and well-tolerated treatment for patients with low-grade lymphoma and a low tumor burden...
  2. ncbi Follicular lymphoma international prognostic index
    Philippe Solal-Celigny
    Centre Jean Bernard, 9 rue Beauverger, 72000 Le Mans, France
    Blood 104:1258-65. 2004
    ..Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments...
  3. ncbi Prognosis of follicular lymphomas
    Philippe Solal-Celigny
    Department of Hematology and Medical Oncology, Centre Jean Bernard, Le Mans, France
    Clin Lymphoma 6:21-5. 2005
    ..This index, together with new biologic markers such as gene profiling and proteomics, could help provide an optimal treatment option for patients with follicular lymphoma...
  4. ncbi Safety of rituximab maintenance therapy in follicular lymphomas
    Philippe Solal-Celigny
    Department of Hematology and Medical Oncology, Jean Bernard Cancer Centre, Le Mans, France
    Leuk Res 30:S16-21. 2006
    ..Findings to date thus indicate that rituximab maintenance therapy is well tolerated, but further assessment of the long-term effects of prolonged B-cell depletion is still required...
  5. ncbi Increasing treatment options in indolent non-Hodgkin's lymphoma
    Philippe Solal-Celigny
    Jean Bernard Cancer Centre, Le Mans, France
    Semin Oncol 29:2-6. 2002
    ..The optimal role of rituximab in first-line therapy for indolent NHL will be determined through randomized clinical trials...
  6. ncbi Follicular Lymphoma International Prognostic Index
    Philippe Solal-Celigny
    Centre Jean Bernard, 9 rue Beauverger, 72000 Le Mans, France
    Curr Treat Options Oncol 7:270-5. 2006
    ..This index, together with new biologic markers such as gene profiling and proteomics, could help provide an optimal treatment option for patients with follicular lymphoma...
  7. ncbi What is the optimal prognostic tool for the assessment of patients with newly diagnosed follicular lymphoma?
    Philippe Solal-Celigny
    Centre Jean Bernard, Le Mans, France
    Leuk Lymphoma 48:452-3. 2007
  8. ncbi [Monoclonal anti-CD20 antibody therapy]
    Laurence Juhel
    Centre Jean Bernard, Le Mans
    Rev Prat 54:711-2. 2004
  9. ncbi Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks
    Gérard Ganem
    Department of Radiation Oncology, Centre Jean Bernard, Le Mans, France
    Int J Radiat Oncol Biol Phys 78:975-82. 2010
    ..Follicular lymphoma is probably an ideal model to explore these mechanisms. This review also discusses the future of LDRT for follicular lymphoma...